C07D - Heterocyclic compounds

More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)

Patents for C07D - Heterocyclic compounds (10,420)
07/2010
07/21/2010	EP1399445B9 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
07/21/2010	CN1751031B HIV replication inhibiting pyrimidines
07/20/2010	US7759486 2,4,5-Trisubstituted pyrimidine compounds
07/20/2010	US7759361 treating a cancer, autoimmune diseases and cardiovscular disorders comprising administering drugs such as Isobutyric acid 2-isobutyryloxymethyl-3-oxo-1-aza-bicyclo[2.2.2]oct-ylmethyl ester; antiproliferative agents
07/20/2010	US7759346 [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
07/13/2010	CA2448303C Biologically active methylene blue derivatives
07/08/2010	US20100172834 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
07/07/2010	CN1615166B Device for mini-invasive ultrasound treatment of an object by a heat-isolated transducer
07/06/2010	US7749999 Alpha-ketoamides and derivatives thereof
07/06/2010	CA2397497C Process for the preparation of 5-carboxyphthalide and its use for the production of citalopram
06/2010
06/30/2010	EP1841763B1 5-heteroaryl thiazoles and their use as pi3k inhibitors
06/30/2010	CN101759645A P38 inhibitors and methods of use thereof
06/29/2010	US7745481 Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
06/29/2010	US7745466 Magnesium salt of S-omeprazole trihydrate of crystal form and another drug such as NSAID, antibiotic, antacid, alginates or prokinetic agents; gastric acid secretion inhibitor, and is useful as an antiulcer agent
06/29/2010	US7745465 Antiischemic agents; antiinflammatory agents; antiallergens; autoimmune disease
06/29/2010	US7745426 vitamin B6-based component selected from pyridoxal, pyridoxamine or pyridoxine chemically linked to antiepileptic agents, neuroprotectants, neurotransmitters or nootropic agents, used for the treatment of epilepsy
06/29/2010	CA2442881C New process for the industrial synthesis of the tetraesters of 5-[bis(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis ofbivalent salts of ranelic acid and their hydrates
06/24/2010	US20100160343 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by vla-4
06/24/2010	US20100160341 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by vla-4
06/23/2010	CN1821236B Therapeutic heterocyclic compounds
06/22/2010	US7741362 4-amino-(S)-2-N-(4-methyl-1-naphthalenesulfonyl)amino-N'-(1,2,3,4-tetrahydro-1-naphthyl)butanamide, arylsulfonylamino based peptidomimetics used for imaging tissues and/or organs such as brain, blood vessels or tumors; medical diagnosis
06/22/2010	US7741338 mixtures comprising a polyene macrolide antibiotic and an antioxidant such as 2,6-di-tert.-butyl-4-methylphenol, that improves the stability of the polyene macrolide to oxidation
06/22/2010	US7741328 Treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or Crohn's disease; Very Late Antigen-4 (VLA-4), also called alpha 4 beta 1 integrin; N-(sulfonamido-substituted pyrimidyl, pyridyl or pyrazyl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine compounds
06/17/2010	US20100152185 Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
06/16/2010	CN1982308B Substituted pyrazoles
06/16/2010	CN1863806B 4-biphenylsubstituted pyrazolidin-3,5-dione derivatives
06/16/2010	CN1829711B Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, process for their preparation and pharmaceutical compositions containing them
06/16/2010	CN1694871B Imidazolopyridines and methods of making and using the same
06/16/2010	CN101735131A New salts
06/16/2010	CN101099462B Composition for controlling harmful bio-organisms and method for controlling harmful bio-organisms using the same
06/15/2010	US7737161 such as 5-amino-N-(5-chloropyridin-2-yl)-3-{[(trans-4-pyrrolidin-1-ylcyclohexyl)carbonyl]amino}furo[3,2-b]pyridine-2-carboxamide, used as activated blood coagulation factor X inhibitors
06/15/2010	CA2379103C Novel spiro compounds
06/15/2010	CA2299495C Process for preparing growth hormone secretagogues
06/10/2010	US20100144771 Novel Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases
06/09/2010	CN1926108B Non-nucleotide reverse transcriptase inhibitors
06/09/2010	CN1780835B Novel fused heterocycles and uses thereof
06/09/2010	CN101723948A C-6 modified indazolylpyrrolotriazines
06/08/2010	US7732439 Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy
06/03/2010	US20100137243 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents
06/02/2010	EP2191832A1 Quinazoline derivatives which promote the release of parathyroid hormone
06/01/2010	US7728147 catalytic hydrogenation in aqueous solution comprising hydrochloric acid, concentrating, distilling; avoids use of isopropanol and ethylacetate solvents; animal sedation
06/01/2010	US7727997 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
06/01/2010	CA2481217C Process for preparing acid salts of gemifloxacin
05/2010
05/26/2010	CN1839116B Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
05/26/2010	CN1713907B N-substituted pyrrolidin derivatives as dipeptidyl peptidase IV inhibitors
05/26/2010	CN1391469B Npyy5拮抗剂 Npyy5 antagonist
05/25/2010	US7723373 3-(Aryl or heteroaryl)sulfonyl- or sulfinyl-1-indoleacetic acid derivatives, e.g., 3 -[(4-chlorophenyl)sulfonyl]-2,5-dimethyl-1H-indol-1-acetic acid; treating asthma, rhinitis and other diseases in which raised levels of PGD2 or its metabolites
05/25/2010	US7723349 N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions
05/25/2010	US7723333 used in treating and/or preventing cardiovascular disorders, inflammatory diseases, Alzheimer's disease, dyslipidemia and metabolic syndrome
05/18/2010	US7718690 e.g. [2-(1-(Benzenesulfonyl)-1H-indol-3-yloxy)ethyl]dimethylamine; serotonin, melatonin receptor ligand; antidepressant, anxiolytic agent; cognition activator; psychosis, schizophrenia, migraine headache, drug addiction, convulsions, osteoporosis, ischemic stroke, Alzheimer's, Parkinson's diseases
05/18/2010	US7718686 Gastrointestinal disorders; irritable bowel syndrome
05/18/2010	CA2430508C Condensed purine derivatives as a1 adenosine receptor antagonists
05/13/2010	US20100120808 Spirocyclic heterocyclic derivatives and methods of their use
05/12/2010	EP1564210B9 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
05/12/2010	CN1762957B 2,3-dihydro-1-indene compound and preparation method thereof
05/11/2010	US7714009 Nitrogen-containing fused heterocyclic compounds
05/11/2010	CA2318696C Triazepinones, process for their preparation and their therapeutic application
05/05/2010	CN1832925B New P2X7 receptor avtagonists and their use
05/04/2010	US7709506 Kinase inhibitors to mediate disease and as antiinflammatory agents
05/04/2010	US7709487 Sulfonyl-derivatives as novel inhibitors of histone deacetylase
05/04/2010	US7709479 Quinazoline derivatives and their use as pharmaceuticals
04/2010
04/29/2010	US20100105920 Preparation of isoxazolin-3-ylacylbenzenes
04/29/2010	US20100105712 Chemical compounds
04/29/2010	US20100105681 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
04/27/2010	US7705033 Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
04/27/2010	US7705006 Anti-cancer cyclopenta[g]quinazoline compounds
04/27/2010	US7704999 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
04/27/2010	US7704998 Sulfonyl-derivatives as novel inhibitors or histone deacetylase
04/27/2010	CA2449180C Viral polymerase inhibitors
04/21/2010	EP2177520A1 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors
04/21/2010	EP1761494B1 Chemical compounds i
04/21/2010	EP1610780B1 Cyclic protein tyrosine kinase inhibitors
04/21/2010	EP1250328B2 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
04/20/2010	US7700783 Synthesis of discodermolide and variants thereof
04/20/2010	US7700763 3-triazolyl-galactoside inhibitors of galectins
04/20/2010	US7700617 Salt of naphthyridine carboxylic acid derivative
04/20/2010	US7700604 (5S)-5-methyl-5-({[6-[2-(trifluoromethyl)pyrimidin-5-yl]-3,4-dihydroisoquinolin-2(1H)-yl]sulfonyl}methyl)imidazolidine-2,4-dione; asthma, rhinitis, chronic obstructive pulmonary diseases (COPD), arthritis (such as rheumatoid arthritis and osteoarthritis), atherosclerosis, cancer
04/20/2010	US7700591 to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis
04/20/2010	US7700329 Methods for making simvastatin and intermediates
04/15/2010	US20100094017 Using alkylmetal reagents for directed metalation of azaaromatics
04/15/2010	US20100093785 Diamine derivatives
04/15/2010	US20100093735 Cytokine inhibitors
04/15/2010	US20100093734 Cytokine inhibitors
04/14/2010	EP1633727B1 Improved production of the rosuvastatin calcium salt
04/14/2010	EP1294922B1 Treating cancer using organelle crystallizing agents
04/14/2010	CN101692832A Composition for controlling harmful bio-organisms and method for controlling harmful bio-organisms using the same
04/13/2010	US7696217 N-(pyridin-2-ylmethyl)-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -acetamide; enhancement of weakened muscle tone; osteoporosis, bone disorders; ; periodontal disease, frailty, aging skin, male hypogonadism, postmenopausal symptoms, inflammatory arthritis, cachexia, Alzheimer's disease
04/13/2010	US7696214 Confining solid tumors; administering a tyrosine kinase inhibitor as antitumor agents; 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
04/13/2010	US7696206 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
04/13/2010	CA2432303C Pyrazole compounds useful as protein kinase inhibitors
04/13/2010	CA2425440C Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
04/06/2010	US7691875 Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof
04/06/2010	CA2453383C Piperidine derivatives as nmda receptor antagonists
04/06/2010	CA2397636C Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
04/06/2010	CA2351709C Novel triazolo(4,5-d)pyrimidine compounds
03/2010
03/31/2010	EP1756111B1 Alkyl substituted indoloquinoxalines
03/30/2010	US7687535 Substituted 3-sulfur indoles
03/30/2010	CA2572508C One pot synthesis of 2-oxazolidinone derivatives
03/25/2010	US20100077497 Ip-10 antibodies and their uses
03/24/2010	EP1615699B1 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ... 105